Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guérin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective comparison
Open Access
- 1 January 2013
- journal article
- research article
- Published by Medknow in Urology Annals
- Vol. 5 (1), 7-12
- https://doi.org/10.4103/0974-7796.106873
Abstract
Aim: The aim was to compare patients' morbidity and response of bacillus Calmette-Guérin (BCG) prophylaxis after the intravesical instillation of low-dose Tokyo 172 strain and regular dose Connaught strain in patients with nonmuscle invasive bladder cancer (NMIBC). Patients and Methods: This was a randomized, active-controlled, open-label, monocenter study. Thirty-eight, NMIBC patients were treated sequentially, in a random order, with low-dose Tokyo 172 strain and regular dose Connaught strain, receiving each therapy for 6 weeks. A total of 18 and 20 patients were randomly assigned to a Tokyo 172 strain arm and a Connaught strain arm, respectively. Complication, morbidity, and recurrence-free survival (RFS) after each treatment were compared. Results: There was no significant difference in the 1-year RFS rate in patients treated with Tokyo 172 strain and Connaught strain (72.2% vs. 83.5%, respectively; P = 0.698). There were no significant differences in adverse events between the arms. Severe adverse events (>Grade 3) were seen in 15% of the Connaught strain group while no severe adverse events were observed as a result of Tokyo 172 strain. Conclusion: Our results indicated that low-dose Tokyo 172 strain decreased adverse events although it was not significant, and the RFS difference was not statistically significant between the two arms. Further investigation is warranted.Keywords
This publication has 20 references indexed in Scilit:
- Low dose BCG regimen in T1 transitional cell carcinoma of the bladder: long term results.2009
- Low-Dose Instillation Therapy with Bacille Calmette-Guérin Tokyo 172 Strain After Transurethral Resection: Historical Cohort StudyUrology, 2008
- Impact of Previous Bacille Calmette-Guérin Failure Pattern on Subsequent Response to Bacille Calmette-Guérin Plus Interferon Intravesical TherapyUrology, 2008
- Long-term Outcome of a Low-dose Intravesical Bacillus Calmette–Guerin Therapy for Carcinoma In Situ of the Bladder: Results After Six Successive Instillations of 40 mg BCGJapanese Journal of Clinical Oncology, 2005
- THE ABLATIVE EFFECT OF QUARTER DOSE BACILLUS CALMETTE-GUERIN ON A PAPILLARY MARKER LESION OF THE BLADDERJournal of Urology, 2001
- Bacillus calmette-Guérin plus intravesical interferon alpha-2b in patients with superficial bladder cancerUrology, 1996
- Five-year results of a phase ii study with low-dose bacille calmette-guérin therapy in high-risk superficial bladder cancerUrology, 1995
- Low‐dose bacille Calmette‐Guerin (BCG) therapy in superficial high‐risk bladder cancer: a phase II study with the BCG strain Connaught CanadaBJU International, 1995
- Low-dose BCG in superficial bladder cancer with strain connaught Canada—As effective as strain pasteur Paris?European Journal of Cancer, 1994
- ABLATIVE AND PROPHYLACTIC EFFECTS OF BCG TOKYO 172 STRAIN FOR INTRAVESICAL TREATMENT IN PATIENTS WITH SUPERFICIAL BLADDER CANCER AND CARCINOMA IN SITU OF THE BLADDERThe Japanese Journal of Urology, 1992